Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cyclosporine and analogues--isolation and synthesis--mechanism of action and structural requirements for pharmacological activity.

Literature DB >> 3546034

Cyclosporine and analogues--isolation and synthesis--mechanism of action and structural requirements for pharmacological activity.

R M Wenger.

Abstract

Entities: Chemical

Mesh：

Substances：
Cyclosporins

Year: 1986 PMID： 3546034 DOI： 10.1007/978-3-7091-8888-0_4

Source DB: PubMed Journal: Fortschr Chem Org Naturst ISSN： 0071-7886

Keyword Cloud
Cited

× No keyword cloud information.

8 in total

1. MS(n) characterization of protonated cyclic peptides and metal complexes.

Authors: Sheldon M Williams; Jennifer S Brodbelt
Journal: J Am Soc Mass Spectrom Date: 2004-07 Impact factor: 3.109

2. Synthesis of non-proteinogenic (D)- or (L)-amino acids by asymmetric hydrogenation.

Authors: H J Kreuzfeld; C Döbler; U Schmidt; H W Krause
Journal: Amino Acids Date: 1996-09 Impact factor: 3.520

3. Synthesis and Characterization of Bodipy-FL-Cyclosporine A as a Substrate for Multidrug Resistance-Linked P-Glycoprotein (ABCB1).

Authors: Andaleeb Sajid; Natarajan Raju; Sabrina Lusvarghi; Shahrooz Vahedi; Rolf E Swenson; Suresh V Ambudkar
Journal: Drug Metab Dispos Date: 2019-08-01 Impact factor: 3.922

4. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.

Authors: Roger G Ptak; Philippe A Gallay; Dirk Jochmans; Andrew P Halestrap; Urs T Ruegg; Luke A Pallansch; Michael D Bobardt; Marie-Pierre de Béthune; Johan Neyts; Erik De Clercq; Jean-Maurice Dumont; Pietro Scalfaro; Kamel Besseghir; Roland M Wenger; Brigitte Rosenwirth
Journal: Antimicrob Agents Chemother Date: 2008-01-22 Impact factor: 5.191

Cyclosporine and analogues--isolation and synthesis--mechanism of action and structural requirements for pharmacological activity.

1. MS(n) characterization of protonated cyclic peptides and metal complexes.

2. Synthesis of non-proteinogenic (D)- or (L)-amino acids by asymmetric hydrogenation.

3. Synthesis and Characterization of Bodipy-FL-Cyclosporine A as a Substrate for Multidrug Resistance-Linked P-Glycoprotein (ABCB1).

4. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.

5. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease.

6. Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms.

7. Preventing P-gp Ubiquitination Lowers Aβ Brain Levels in an Alzheimer's Disease Mouse Model.

8. Protecting P-glycoprotein at the blood-brain barrier from degradation in an Alzheimer's disease mouse model.